Mehta Vimal bought BTAI
May 1, 2026 · Form 4 insider transaction
Mehta Vimal bought 18,000 shares of BioXcel Therapeutics, Inc., a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 6 days after the transaction.
Direction
Acquired (buy-side)
Shares
18,000
Price
N/A
Total value
N/A
InsiderMehta Vimal
Role—
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateMay 1, 2026
Filing dateMay 7, 2026
Shares owned after39,259
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.